Mary Pinder-Schenck

Mary Pinder-Schenck, MD, currently serves as Senior Vice President at Revolution Medicines since July 2024. Prior experience includes roles such as Vice President and Head of Global Oncology Medical Affairs at Daiichi Sankyo, Inc., and Vice President and Head of US Medical Affairs at Kite Pharma. Earlier positions at Merck encompassed Vice President and Executive Director roles in Global Medical Affairs Oncology. Mary Pinder-Schenck's career includes significant contributions at GSK, where leadership spanned various aspects of medical affairs and clinical development in oncology. Notable earlier roles involved serving as Assistant Professor at H Lee Moffitt Cancer Center and Medical Oncologist at Virginia Mason Institute, complemented by formative years in fellowship at MD Anderson Cancer Center and residency at the University of North Carolina. Mary Pinder-Schenck earned an MD from Stanford University School of Medicine and a BA in English from Wellesley College.